SCHEMBL473980

SCHEMBL473980

CCOC(=O)c1cc(Cl)ccc1B(O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.51
TSHR P16473 2/20 0.50
MAOB P27338 1/20 0.49
ALOX15 P16050 3/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
MAPK10 P53779 1/20 0.48
KDM4E B2RXH2 4/20 0.48
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 2/20 0.47
CASP1 P29466 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952924 1.00 MAPK1 (0.51) MAPK1TSHRMAOBALOX15KMT2A
SCHEMBL19763606 0.90 MAPK1 (0.46) MAPK1TSHRMAOBALOX15KMT2A
SCHEMBL6516041 0.89 MAOB (0.51) MAPK1TSHRMAOBALOX15KMT2A
SCHEMBL235046 0.84 TSHR (0.60) MAPK1TSHRMAOBALOX15KMT2A
SCHEMBL11225504 0.83 CYP4F2 (0.67) MAPK1TSHRALOX15KMT2AKDM4E
SCHEMBL549144 0.83 MAPK1 (0.54) MAPK1TSHRMAOBALOX15KMT2A
SCHEMBL29958024 0.82 TSHR (0.54) MAPK1TSHRKMT2AMEN1KDM4E
SCHEMBL19893894 0.82 TSHR (0.54) MAPK1TSHRKMT2AMEN1KDM4E
SCHEMBL27711843 0.81 MAPK1 (0.47) MAPK1TSHRMAOBALOX15KMT2A
SCHEMBL19971601 0.81 MAPK1 (0.52) MAPK1TSHRMAOBALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11672791-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2023-06-13 US disclosed
US-11672791-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2023-06-13 US disclosed
US-20230012676-A1 TYROSINE KINASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2023-01-19 US disclosed
EP-3481826-B1 TYROSINE KINASE INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2021-11-03 EP disclosed
US-11110082-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2021-09-07 US disclosed
US-20200078348-A1 TYROSINE KINASE INHIBITORS MIDCAP FINANCIAL TRUST 2020-03-12 US disclosed
US-10434096-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2019-10-08 US disclosed
EP-3481826-A1 TYROSINE KINASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2019-05-15 EP disclosed
US-20190099411-A1 TYROSINE KINASE INHIBITORS MIDCAP FINANCIAL TRUST 2019-04-04 US disclosed
US-10130623-B2 Tyrosine kinase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2018-11-20 US disclosed
US-7795247-B2 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-09-14 US disclosed
WO-2010051237-A1 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed
WO-2010051237-A1 2,5-DISUBSTITUTED PHENYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
EP-2102198-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-23 EP disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed
WO-2008071311-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-06-19 WO disclosed
EP-1807403-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-07-18 EP disclosed
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) 2006-05-11 US disclosed
WO-2006046030-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10130623-B2 Tyrosine kinase inhibitors TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885
US-20190099411-A1 TYROSINE KINASE INHIBITORS TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents IDO1, ZC3HAV1, IDO2 MAPK1 3736/4885TSHR 246/4885MAOB 259/4885
US-11110082-B2 Tyrosine kinase inhibitors TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS PPARD, PPARG, PPARA MAPK1 737/4885TSHR 269/4885MAOB 2786/4885
US-20230012676-A1 TYROSINE KINASE INHIBITORS TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885
US-10434096-B2 Tyrosine kinase inhibitors TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885
US-11672791-B2 Tyrosine kinase inhibitors TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885
US-20200078348-A1 TYROSINE KINASE INHIBITORS TYRO3, AXL, RET MAPK1 327/4885TSHR 295/4885MAOB 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.